ANDA 204954, held by Quagen Pharmaceuticals. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 204954 (Methylphenidate Hydrochloride), held by Quagen Pharmaceuticals, was first approved by FDA on Jan 26, 2017, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 26, 2017 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride2.5MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride5MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride10MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Discontinued |
| Oct 13, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 25, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 26, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters